How much did Shield Therapeutics achieve in EBIT for the current year?
In the current year, Shield Therapeutics has achieved an EBIT of -15.18 M GBP.
Shield Therapeutics EBIT 2024
Shield Therapeutics EBIT
-15.18 M GBP
Ticker
STX.L
ISIN
GB00BYV81293
WKN
A2AE98
In 2024, Shield Therapeutics's EBIT was -15.18 M GBP, a -51.55% increase from the -31.33 M GBP EBIT recorded in the previous year.
The Shield Therapeutics EBIT history
| YEAR | EBIT (undefined GBP) |
|---|---|
| 2027e | 4.53 |
| 2026e | -3.48 |
| 2025e | -4.82 |
| 2024e | -15.18 |
| 2023 | -31.33 |
| 2022 | -31.65 |
| 2021 | -20.29 |
| 2020 | -2.15 |
| 2019 | -9.04 |
| 2018 | -5.16 |
| 2017 | -20.95 |
| 2016 | -12.29 |
| 2015 | -6.43 |
| 2014 | -3.39 |
| 2013 | -3.84 |
| 2012 | -3.61 |
Shield Therapeutics Revenue, EBIT, Net Income GB00BYV81293 · A2AE98
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Shield Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Shield Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Shield Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Shield Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Shield Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Shield Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Shield Therapeutics’s growth potential.
Shield Therapeutics Revenue, EBIT and net profit per share
| Date | Shield Therapeutics Revenue | Shield Therapeutics EBIT | Shield Therapeutics Net Income |
|---|---|---|---|
| 2027e | 72.53 M undefined | 4.53 M undefined | 2.5 M undefined |
| 2026e | 53.46 M undefined | -3.48 M undefined | -5.18 M undefined |
| 2025e | 58.76 M undefined | -4.82 M undefined | -7.84 M undefined |
| 2024e | 29.22 M undefined | -15.18 M undefined | -15.9 M undefined |
| 2023 | 13.09 M undefined | -31.33 M undefined | -33.29 M undefined |
| 2022 | 5.5 M undefined | -31.65 M undefined | -49.79 M undefined |
| 2021 | 1.52 M undefined | -20.29 M undefined | -19.68 M undefined |
| 2020 | 10.39 M undefined | -2.15 M undefined | -2.63 M undefined |
| 2019 | 719,000 undefined | -9.04 M undefined | -8.8 M undefined |
| 2018 | 11.88 M undefined | -5.16 M undefined | -1.79 M undefined |
| 2017 | 637,000 undefined | -20.95 M undefined | -19.59 M undefined |
| 2016 | 304,000 undefined | -12.29 M undefined | -15.02 M undefined |
| 2015 | 0 undefined | -6.43 M undefined | -23.63 M undefined |
| 2014 | 0 undefined | -3.39 M undefined | -12.91 M undefined |
| 2013 | 0 undefined | -3.84 M undefined | -4.19 M undefined |
| 2012 | 0 undefined | -3.61 M undefined | -3.15 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2012 | 0 GBP | -3.61 M GBP | -3.15 M GBP |
| 2013 | 0 GBP | -3.84 M GBP | -4.19 M GBP |
| 2014 | 0 GBP | -3.39 M GBP | -12.91 M GBP |
| 2015 | 0 GBP | -6.43 M GBP | -23.63 M GBP |
| 2016 | 304,000 GBP | -12.29 M GBP | -15.02 M GBP |
| 2017 | 637,000 GBP | -20.95 M GBP | -19.59 M GBP |
| 2018 | 11.88 M GBP | -5.16 M GBP | -1.79 M GBP |
| 2019 | 719,000 GBP | -9.04 M GBP | -8.8 M GBP |
| 2020 | 10.39 M GBP | -2.15 M GBP | -2.63 M GBP |
| 2021 | 1.52 M GBP | -20.29 M GBP | -19.68 M GBP |
| 2022 | 5.5 M GBP | -31.65 M GBP | -49.79 M GBP |
| 2023 | 13.09 M GBP | -31.33 M GBP | -33.29 M GBP |
| 2024e | 29.22 M GBP | -15.18 M GBP | -15.9 M GBP |
| 2025e | 58.76 M GBP | -4.82 M GBP | -7.84 M GBP |
| 2026e | 53.46 M GBP | -3.48 M GBP | -5.18 M GBP |
| 2027e | 72.53 M GBP | 4.53 M GBP | 2.5 M GBP |
Shield Therapeutics stock margins GB00BYV81293 · A2AE98
The Shield Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Shield Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Shield Therapeutics.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Shield Therapeutics's sales revenue. A higher gross margin percentage indicates that the Shield Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Shield Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Shield Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Shield Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Shield Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Shield Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Shield Therapeutics Margin History
| Shield Therapeutics Gross margin | Shield Therapeutics Profit margin | Shield Therapeutics EBIT margin | Shield Therapeutics Profit margin |
|---|---|---|---|
| 2027e | 30.78 % | 6.25 % | 3.44 % |
| 2026e | 30.78 % | -6.5 % | -9.69 % |
| 2025e | 30.78 % | -8.2 % | -13.34 % |
| 2024e | 30.78 % | -51.96 % | -54.44 % |
| 2023 | 30.78 % | -239.44 % | -254.44 % |
| 2022 | 44.7 % | -575.49 % | -905.42 % |
| 2021 | 35.48 % | -1,336.01 % | -1,295.46 % |
| 2020 | 86.96 % | -20.74 % | -25.32 % |
| 2019 | 32.55 % | -1,256.61 % | -1,223.92 % |
| 2018 | 97.38 % | -43.42 % | -15.08 % |
| 2017 | 75.67 % | -3,289.01 % | -3,075.04 % |
| 2016 | 67.11 % | -4,043.75 % | -4,939.47 % |
| 2015 | 30.78 % | 0 % | 0 % |
| 2014 | 30.78 % | 0 % | 0 % |
| 2013 | 30.78 % | 0 % | 0 % |
| 2012 | 30.78 % | 0 % | 0 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2012 | 30.78 % | 0 % | 0 % |
| 2013 | 30.78 % | 0 % | 0 % |
| 2014 | 30.78 % | 0 % | 0 % |
| 2015 | 30.78 % | 0 % | 0 % |
| 2016 | 67.11 % | -4,043.75 % | -4,939.47 % |
| 2017 | 75.67 % | -3,289.01 % | -3,075.04 % |
| 2018 | 97.38 % | -43.42 % | -15.08 % |
| 2019 | 32.55 % | -1,256.61 % | -1,223.92 % |
| 2020 | 86.96 % | -20.74 % | -25.32 % |
| 2021 | 35.48 % | -1,336.01 % | -1,295.46 % |
| 2022 | 44.7 % | -575.49 % | -905.42 % |
| 2023 | 30.78 % | -239.44 % | -254.44 % |
| 2024e | 30.78 % | -51.96 % | -54.44 % |
| 2025e | 30.78 % | -8.2 % | -13.34 % |
| 2026e | 30.78 % | -6.5 % | -9.69 % |
| 2027e | 30.78 % | 6.25 % | 3.44 % |
Shield Therapeutics Aktienanalyse
What does Shield Therapeutics do?
The company Shield Therapeutics PLC is a renowned British pharmaceutical conglomerate, founded in 2008. Based in Gateshead, England, Shield Therapeutics specializes in the development and marketing of pharmaceutical products, with a particular focus on iron deficiency anemia. The company also has a strong presence in Europe and Asia. Shield Therapeutics' business model is to provide high-quality and innovative medical solutions to improve people's health and well-being. The company continuously researches new products to better cater to the needs of patients and doctors. The focus of Shield Therapeutics is on combating iron deficiency anemia, a severe blood disorder caused by a lack of iron in the body. Iron deficiency can be attributed to various factors, such as inadequate food intake, blood loss, or iron deficiency accumulation due to diseases. This anemia can lead to a range of symptoms, including fatigue, weak muscles, and dizziness. Long-term consequences can include life-threatening complications such as heart failure and strokes. Shield Therapeutics offers various products that can be used to treat iron deficiency anemia, such as Feraccru (in injection form) and Accrufer / Accrufer Tablets (in tablet form). Feraccru is an orally absorbed iron preparation indicated for the treatment of anemia in adults with iron deficiency anemia. Accrufer / Accrufer Tablets is an iron salt complex that is rapidly absorbed and shows high efficacy. The company also has its own research and development department, which focuses on researching innovative therapies and treatment methods. Shield Therapeutics actively participates in clinical research and the development of new therapeutic options aimed at improving the quality of life for people with iron deficiency anemia. More recently, Shield Therapeutics has also ventured into other disease areas. The company has developed clinical studies in collaboration with a top 10 pharmaceutical company to modify atherosclerosis through iron chelators. This is a groundbreaking research field that aims to develop advanced therapies for the treatment of infertility and chronic obstructive pulmonary disease (COPD). Overall, Shield Therapeutics has experienced strong growth in recent years and has solidified its position as a leading provider of pharmaceutical products for the treatment of iron deficiency anemia. The company has developed a wide range of products and can rely on a strong research and development department that constantly faces new challenges and offers innovative solutions for a variety of health issues. If Shield Therapeutics continues to be successful, it will undoubtedly continue to play a significant role in the industry. Answer: The company Shield Therapeutics specializes in the development and marketing of pharmaceutical products, with a particular focus on iron deficiency anemia. Shield Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing Shield Therapeutics's EBIT
Shield Therapeutics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of Shield Therapeutics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
Shield Therapeutics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in Shield Therapeutics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about Shield Therapeutics stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Shield Therapeutics.
How has the EBIT of Shield Therapeutics developed in recent years?
The EBIT of Shield Therapeutics has increased by -51.547% decreased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company Shield Therapeutics?
The EBIT of Shield Therapeutics is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does Shield Therapeutics pay?
Over the past 12 months, Shield Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Shield Therapeutics is expected to pay a dividend of 0 GBP.
What is the dividend yield of Shield Therapeutics?
The current dividend yield of Shield Therapeutics is .
When does Shield Therapeutics pay dividends?
Shield Therapeutics pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Shield Therapeutics?
Shield Therapeutics paid dividends every year for the past 0 years.
What is the dividend of Shield Therapeutics?
For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.
In which sector is Shield Therapeutics located?
Shield Therapeutics is assigned to the 'Health' sector.
Wann musste ich die Aktien von Shield Therapeutics kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Shield Therapeutics from 9/9/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 9/9/2024.
When did Shield Therapeutics pay the last dividend?
The last dividend was paid out on 9/9/2024.
What was the dividend of Shield Therapeutics in the year 2023?
In the year 2023, Shield Therapeutics distributed 0 GBP as dividends.
In which currency does Shield Therapeutics pay out the dividend?
The dividends of Shield Therapeutics are distributed in GBP.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Shield Therapeutics
Our stock analysis for Shield Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Shield Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Shield Therapeutics Revenue
- Shield Therapeutics Net Income
- Shield Therapeutics P/E
- Shield Therapeutics P/S
- Shield Therapeutics EBIT
- Shield Therapeutics Dividend
- Shield Therapeutics Stocks
- Shield Therapeutics Market capitalization
- Shield Therapeutics Debt
- Shield Therapeutics Liabilities
- Shield Therapeutics Equity
- Shield Therapeutics AAQS
- Shield Therapeutics Employees
- Shield Therapeutics ROE
- Shield Therapeutics ROA
- Shield Therapeutics ROCE
